83802-71-5

Basic information

• Product Name: 5-Fluoro-6-methoxyindan-1-one
• Synonyms: 5-Fluoro-6-methoxyindan-1-one;5-fluoro-2,3-dihydro-6-Methoxyinden-1-one;5-Fluoro-6-Methoxy-2,3-dihydro-1H-inden-1-one;5-Fluoro-6-Methoxy-1-indanone;5-FLUORO-2,3-DIHYDRO-6-METHOXY-1H-INDEN-1-ONE;5-fluoro-6-methoxy-inden-1-one
• CAS NO: 83802-71-5
• Molecular Formula: C₁₀H₉FO₂
• Molecular Weight: 180.18
• Mol File: 83802-71-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 312 °C at 760 mmHg
• Flash Point: 137.9 °C
• Appearance: /
• Density: 1.257 g/cm³
• Vapor Pressure: 0.000543mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Fluoro-6-methoxyindan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-6-methoxyindan-1-one(83802-71-5)
• EPA Substance Registry System: 5-Fluoro-6-methoxyindan-1-one(83802-71-5)

Safety Data

• Hazardous Substances Data: 83802-71-5(Hazardous Substances Data)

Usage

General Description

5-Fluoro-6-methoxyindan-1-one is a chemical compound with the molecular formula C10H9FO2. It is a synthetic pharmaceutical compound that belongs to the class of indanone derivatives. 5-Fluoro-6-methoxyindan-1-one has potential applications in the development of new drugs and pharmaceuticals, particularly in the field of medicinal chemistry. It is known for its ability to interact with certain biological targets, which makes it a potential candidate for the development of new therapeutic agents. Research on 5-Fluoro-6-methoxyindan-1-one is ongoing, and its potential uses and properties are still being explored.

InChI:InChI=1/C10H9FO2/c1-13-10-5-7-6(4-8(10)11)2-3-9(7)12/h4-5H,2-3H2,1H3

Upstream product

• 69888-90-0 3-(3-fluoro-4-methoxyphenyl)propionic acid 
• 713-85-9 3-(3-fluoro-4-methoxyphenyl)acrylic acid 
• 351-54-2 3-fluoro-p-anisaldehyde 
• 83802-70-4 3-(3-fluoro-4-methoxyphenyl)propionyl chloride 

Downstream Products

• 187872-53-3 (E)-(5-fluoro-6-methoxyindan-1-ylidene)-acetonitrile 
• 187871-98-3 (E)-(2,3-dihydro-6-methoxy-1H-inden-1-ylidene)acetonitrile 
• 2676865-61-3 6-fluoro-5-isopropyl-2,3-dihydro-1H-inden-4-amine 
• 2676865-60-2 6-fluoro-4-nitro-5-(prop-1-en-2-yl)-2,3-dihydro-1H-indene 
• 2676865-58-8 6-fluoro-4-nitro-2,3-dihydro-1H-inden-5-ol 
• 917885-01-9 5-fluoro-6-hydroxyindan-1-one 
• 83802-73-7 6-fluoro-5-indanol 
• 83802-72-6 6-fluoro-5-methoxyindan 

Relevant articles and documents

Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate

The acetylcholinesterase (AChE) inhibitors remain key therapeutic drugs for the treatment of Alzheimer's disease (AD). However, the low-safety window limits their maximum therapeutic benefits. Here, a novel kinetics-driven drug design strategy was employed to discover new-generation AChE inhibitors that possess a longer drug-target residence time and exhibit a larger safety window. After detailed investigations, compound 12 was identified as a highly potent, highly selective, orally bioavailable, and brain preferentially distributed AChE inhibitor. Moreover, it significantly ameliorated cognitive impairments in different mouse models with a lower effective dose than donepezil. The X-ray structure of the cocrystal complex provided a precise binding mode between 12 and AChE. Besides, the data from the phase I trials demonstrated that 12 had good safety, tolerance, and pharmacokinetic profiles at all preset doses in healthy volunteers, providing a solid basis for its further investigation in phase II trials for the treatment of AD.

Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders

A compound having the following general fomula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; R5 is H, a halogen atom, C1-6 alkyl group, a C1-6 alkoxy group, a hydroxy group, a nitro group, a cyano group or an amino group wherein the C1-6 alkyl group, the C1-6 alkoxy group and the amino group may be substituted by 1 to 5 substituents, Y is C or N; ring B is an optionally substituted benzene ring; m = 1 to 4 and n = 0 to 2; L represents a leaving group such as a halogen atom, an alkylsulfonyl group, an alkylsulfonlyoxy group and arylsulfonyloxy group; or a salt thereof.

Benzocycloalkene compounds, their production and use

A compound of the formula STR1 wherein R1 and R2 independently represent H or an optionally substituted hydrocarbon group; R3 represents an optionally substituted hydrocarbon group; R4 represents H or a hydrocarbon group; ring A represents a substituted benzene ring; X represents a C2-4 alkylene group etc.; and Y represents a bond or a lower alkylene group, or salts thereof is useful as prophylactic or therapeutic agents of diseases related with melatonin activity.